Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01441232 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics
A Phase 1 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01441232 is a Phase 1 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 18 participants.
The verdict
NCT01441232, a Phase 1 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study is intended to evaluate the pharmacodynamics, safety, and tolerability of LX4211 when administered concurrently with sitagliptin (Januvia®) in patients with Type 2 Diabetes Mellitus.
Interventions
- DRUG LX4211
- DRUG Januvia®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01441232
The ClinicalTrials.gov registry entry for NCT01441232 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which LX4211 is the first listed.
NCT01441232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01441232 about?
NCT01441232 is a clinical study titled "A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics". This study is intended to evaluate the pharmacodynamics, safety, and tolerability of LX4211 when administered concurrently with sitagliptin (Januvia®) in patients with Type 2 Diabetes Mellitus.
What is the current status of trial NCT01441232?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2011-10.
What interventions are being tested in trial NCT01441232?
The interventions under investigation include: LX4211 (DRUG), Januvia® (DRUG).
Who is sponsoring clinical trial NCT01441232?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.